We found that procaspase 8 was overexpressed in non-small-cell lung cancers (NSCLCs) compared with matched normal tissues. The caspase 8 inhibitor FLICE-inhibitory protein (FLIP) was also overexpressed in the majority of NSCLCs. Silencing FLIP induced caspase 8 activation and apoptosis in NSCLC cell lines, but not in normal lung cell lines. Apoptosis induced by FLIP silencing was mediated by the TRAIL death receptors DR4 and DR5, but was not dependent on ligation of the receptors by TRAIL. Furthermore, the apoptosis induced by FLIP silencing was dependent on the overexpression of procaspase 8 in NSCLC cells. Moreover, in NSCLC cells, but not in normal cells, FLIP silencing induced co-localization of DR5 and ceramide, and disruption of this co-localization abrogated apoptosis. FLIP silencing supra-additively increased TRAIL-induced apoptosis of NSCLC cells; however, normal lung cells were resistant to TRAIL, even when FLIP was silenced. Importantly, FLIP silencing sensitized NSCLC cells but not normal cells to chemotherapy in vitro, and silencing FLIP in vivo retarded NSCLC xenograft growth and enhanced the anti-tumour effects of cisplatin. Collectively, our results suggest that due to frequent procaspase 8 overexpression, NSCLCs may be particularly sensitive to FLIP-targeted therapies.
Death receptors such as the TRAIL receptors DR4 and DR5 regulate the extrinsic apoptotic pathway. 1 Classically, activation of death receptors occurs through ligand binding, resulting in recruitment of Fas-associated death domain (FADD), which in turn recruits inactive procaspase 8 (FLICE). 2, 3 The resulting complex is termed the deathinducing signaling complex (DISC). At the DISC, procaspase 8 is activated and subsequently activates executioner caspases 3 and 7, resulting in apoptosis. FLICE-inhibitory protein (FLIP) is a caspase 8 inhibitor and is predominantly expressed as long (FLIP L ) and short (FLIP S ) splice forms. 4 Both FLIP splice forms are recruited to the DISC, preventing the full activation of caspase 8, thereby inhibiting apoptosis. 5 FLIP has been found to be overexpressed in a number of cancers. 6, 7 Although FLIP mRNA expression was found to be more highly expressed in squamous non-small-cell lung cancer (NSCLC) tissues compared with normal tissue, 8 no difference in expression of FLIP L protein was observed between matched tumor and normal tissues. 9 Non-small-cell lung cancer accounts for B80% of lung cancer and is responsible for over one million mortalities worldwide each year. 10 Platinum-based therapies are used in early, locally advanced and metastatic disease; however median survival times are only 8-10 months in the latter setting, and the objective tumor response rate after second line therapy is below 10%. Clearly, new strategies are needed to treat this disease. DR5 has been reported to be overexpressed in a high percentage of primary and metastatic NSCLC. 11 Unlike many SCLCs, in which the caspase 8 gene is frequently silenced by methylation, NSCLCs typically retain caspase 8 expression. 12, 13 In this report, we show that procaspase 8 and FLIP are frequently overexpressed in NSCLCs and that this preferentially sensitizes NSCLC cells to apoptosis induced by FLIP silencing.
Results
Differential expression of procaspase 8 and FLIP in NSCLC versus normal tissue. We analyzed procaspase 8 and FLIP expression in a panel of matched normal and tumor tissues from 20 patients with NSCLC ( Figure 1a) . Expression of the long form of FLIP (FLIP L ) was comparable in tumor and matched normal tissues for most patients, although 5/20 (25%) expressed higher FLIP L in the tumor tissue ( Figures  1a and b) . In 13/20 (65%) patients, expression of the short form of FLIP (FLIP S ) was significantly higher in the tumor than the matched normal tissues (Figures 1a and b) . Most notably, 17/20 (85%) of the tumors had higher procaspase 8 expression in tumor compared with matched normal tissues (Figures 1a and b ). There were no obvious correlations between procaspase 8 or FLIP expression and any clinicopathological details (Table 1) . FLIP was overexpressed only in tumor tissue that also overexpressed procaspase 8, although not all procaspase 8-overexpressing tumors overexpressed FLIP (Figure 1b) . We also examined DR4 and DR5 expression in the patient samples (Supplementary Figure 1a) . Of note, DR4 and DR5 were expressed in every tumor sample. Moreover, DR4 and DR5 expression were similar in the majority of matched normal and tumor tissues, although 5/20 patients actually expressed higher levels of DR4 and/or DR5 in their tumors, and one patient (#12) had lower DR4 and DR5 in their tumor. Procaspase 8 overexpression in NSCLCs suggested that these tumors may be sensitive to caspase 8-mediated apoptosis. To assess this in vitro, we used four NSCLC and two non-cancer 'normal' lung cell lines. The H460 large cell lung cancer cell line, the A549 adenocarcinoma cell line, the H157 squamous cell line and the H727 carcinoid cell line all expressed higher levels of procaspase 8 compared with the non-cancer 34LU lung fibroblast and BEAS-2B bronchial epithelial cell lines (Figure 1c) . Apart from the H727 cell line, T  N  T  N  T  N  T  N  T  N  T  N  T  N  T  N  T  N  T Figure 1c) , indicating that overexpression of procaspase 8 in the NSCLC cell lines is because of posttranscriptional regulation.
The cancer and normal cell line models expressed similar levels of cell surface DR5, with the exception of A549 cells, which expressed significantly higher levels (Figure 1d) . Moreover, western blot analyses indicated overall that, the relative expression of DR5 in the normal and tumor cell line models was similar to the pattern of expression observed in the majority of matched normal and tumor samples (Supplementary Figure 1a ). H460 and A549 cells expressed high levels of DR4 on the cell surface; H157 cells expressed moderate levels and H727 cells expressed low levels. DR4 cell surface expression was barely detectable in the 34LU and BEAS-2B cell lines. By western blot analysis, DR4 was also expressed at a lower level in the BEAS-2B cells compared with the H460 cells (Supplementary Figure 1a) . A549 and 34LU cells expressed relatively high levels of Fas, whereas the other cell lines expressed lower levels (Supplementary Figure 1b) . death after FLIP silencing in H460 cells, and simultaneously downregulating both DR4 and DR5 had a further protective effect ( Figure 3a ). In contrast, silencing Fas had no effect on FLIP siRNA-induced apoptosis ( Figure 3a) . Similar results were observed in the A549 cell line (data not shown). Activation of DR4 and DR5 classically occurs after TRAIL binding; however, expression of membrane-bound TRAIL was very low (B1.5% or less compared to isotype control, data not shown) in the NSCLC cell lines, and neither TRAIL siRNA (data not shown) nor TRAIL-neutralizing antibodies abrogated FLIP silencing-induced cell death ( Figure 3b and Supplementary Figure 2c) . Collectively, these results suggest that apoptosis induction after FLIP silencing is mediated through DR4 and DR5, but is not dependent on ligation of these receptors by TRAIL.
TRAIL can induce super clustering of TRAIL receptors into ceramide-containing lipid rafts.
14 Furthermore, it was shown that TRAIL-induced generation of ceramide and formation of DR5-containing ceramide-enriched membrane domains is dependent on acid sphingomyelinase (ASM) and is necessary for the induction of TRAIL-induced apoptosis. In H460 cells, FLIP silencing resulted in the formation of intense foci on the cell surface, at which ceramide and DR5 were co-localized (Figure 3c ). In contrast, the patterns of ceramide and DR5 expression were similar in control and FLIP siRNA-transfected BEAS-2B cells, indicating that DR5 and ceramide failed to cluster after FLIP silencing in this normal cell model. These results suggest that silencing FLIP preferentially induces TRAIL receptor clustering in cancer cells compared with normal cells. To examine whether the formation of DR5-containing lipid rafts was necessary f or apoptosis induced by FLIP silencing, we used Nystatin, a cholesterol-depleting agent that has been shown to inhibit the redistribution of TRAIL receptors into lipid rafts. 15 We also investigated the role of ASM in FLIP siRNA-induced apoptosis using the ASM inhibitor imipramine. Notably, Nystatin and imipramine both inhibited FLIP siRNA-induced apoptosis in H460 cells (Figure 3d ). Similar results were obtained in A549 cells (data not shown). These results suggest that after FLIP silencing in NSCLC cells, ceramideenriched DR5-containing platforms are formed, and that the formation of these platforms is necessary for the induction of apoptosis. Furthermore, the failure to induce clustering of DR5 into ceramide-enriched lipid rafts may explain the resistance of BEAS-2B cells to apoptosis induced by FLIP siRNA. 
Cross-talk between the extrinsic and intrinsic apoptotic pathways is mediated by Bid, which, when cleaved by caspase 8, translocates to the mitochondria and promotes the release of pro-apoptotic factors. 16 Silencing Bid completely abrogated FLIP siRNA-induced apoptosis in the A549 cell line, but only partially attenuated apoptosis in the H460 cell line (Figure 4d ). These results indicate that the A549 cells must amplify the apoptotic signal through the mitochondria and behave like type II cells after FLIP silencing, whereas the H460 cells behave more like type I cells. 17 Thus, FLIP silencing has the potential to activate apoptosis in both type I and II NSCLC cells.
FLIP siRNA sensitizes NSCLC but not normal lung cells to TRAIL. The H460 cell line was highly sensitive to TRAILinduced cell death, whereas the A549, H727 and H159 cell lines were less sensitive (Figure 5a ). The two normal lung cell lines were completely resistant to TRAIL-induced caspase 8 activation and apoptosis (Figure 5a ). FLIP silencing synergistically increased TRAIL-induced apoptosis in all the NSCLC cell lines (Figure 5b) ; similar results were observed for the Fas agonistic antibody CH-11 ( Figure 5c) . Interestingly, the 34LU and BEAS-2B cell lines were not sensitized to TRAIL or CH-11 treatment after transfection with FLIP siRNA. Furthermore, TRAIL treatment alone and combined treatment with FLIP siRNA and TRAIL both failed to activate caspase 8 in the BEAS-2B cell line (Figures 5d  and Supplementary Figure 1d) . Thus, in contrast to the NSCLC cells, FLIP does not seem to be a critical determinant of TRAIL sensitivity in the normal lung cell line models. In addition, we found that TRAIL-induced apoptosis in the presence and absence of FLIP siRNA co-treatment could be equally mediated by either DR4 or DR5, as only simultaneous silencing of both receptors blocked apoptosis ( Supplementary Figures 2d and e) . Figure 2f) . However, FLIP siRNA failed to sensitize the 34LU or BEAS-2B cell lines to cisplatininduced apoptosis (Figure 6b ). Similar results were observed with Taxol (Paclitaxel, Mayne Pharma, Warwickshire, UK; Supplementary Figures 3a and b) . We also found that silencing FLIP could overcome drug resistance in a cisplatinresistant H460 daughter cell line (unpublished observations).
To assess the effects of targeting FLIP in vivo, we used an H460 xenograft model in Balb/c nude mice. Xenografts that were injected with FLIP siRNA expressed reduced levels of FLIP L and FLIP S compared with SC siRNA-injected xenografts (Figure 6c ). Furthermore, caspase 3 activation was observed in FLIP siRNA injected xenografts indicative of enhanced cell death. Importantly, compared with untreated and siRNA controls, xenografts injected with FLIP siRNA grew significantly more slowly (Figure 6c) . The in vivo effect of FLIP silencing in combination with cisplatin was also examined. Cisplatin treatment retarded xenograft growth to a very similar extent as FLIP siRNA (Figure 6d) . Importantly, the combination of FLIP siRNA and cisplatin further inhibited xenograft growth compared with FLIP siRNA alone or cisplatin alone. Of note, there was almost no tumor growth in FLIP siRNA and cisplatin co-treated mice until after the last day of treatment. These results indicate that downregulating FLIP retarded xenograft growth and enhanced the growth inhibitory effect of cisplatin in vivo.
Discussion
FLIP protein overexpression has been reported in numerous epithelial cancers. 6, 7 Despite overexpression of FLIP mRNA having been reported in squamous NSCLC, no overexpression of FLIP L protein was noted in NSCLC tissues. 9 In this study, we found that FLIP L protein expression was overexpressed in 5/20 of NSCLCs compared with normal tissues. Furthermore, FLIP S was expressed at a higher level in 65% of NSCLCs. Previous studies have shown that unlike SCLCs, NSCLCs express caspase 8 protein. 12, 13 We found that 17/20 of NSCLCs actually had higher procaspase 8 expression than matched normal tissues, and the extent of overexpression was 4two fold for 12/20 patients. Moreover, all but three of the NSCLCs that overexpressed procaspase 8 by 4two fold also overexpressed FLIP. Expression of DR4 and DR5 in the NSCLCs were similar to those in the matched normal tissues for 15/20 patients and were actually higher in NSCLCs in the remaining five patients. Tissue microarrays are currently We have previously shown that FLIP gene silencing induced caspase 8 activation and apoptosis in colorectal cancer cells and that FLIP L was the more important splice form for this phenotype. 18 In the current study, we found that silencing both FLIP L and FLIP S was required for maximal caspase 8, 9 and 3 activation and apoptosis in NSCLC cells. Splice form-specific silencing had only a modest effect on apoptosis in NSCLC cells, suggesting that one splice form can efficiently compensate for loss of the other. Importantly, FLIP gene silencing failed to induce caspase 8 activation and apoptosis in normal lung cell line models. To our knowledge, these are the first studies to suggest that FLIP inhibition preferentially induces apoptosis in cancer cells compared with normal cells.
In agreement with previous studies, 19 we found that TRAIL treatment induced apoptosis in NSCLC cell lines (albeit to varying degrees), but not in normal lung models. Notably, we found that FLIP silencing potently sensitized each NSCLC cell line to TRAIL, but failed to sensitize the normal lung cells. This suggests that although FLIP clearly plays a key role in regulating the sensitivity of NSCLC cells to TRAIL, it may be less important in normal lung cells. These findings have clinical relevance, as a number of TRAIL receptor-targeted therapeutics are in early phase clinical development. 20 Furthermore, Schimmer et al. 21 recently identified a smallmolecule inhibitor of FLIP. Our observations suggest that targeting FLIP may preferentially sensitize NSCLC cells to TRAIL receptor-targeted therapeutics.
Downregulating FLIP has been shown to sensitize colon, ovarian and cervical cancer cells to chemotherapy-induced cell death. [22] [23] [24] We found that silencing FLIP sensitized NSCLC cells to cisplatin-and taxol-induced apoptosis, but failed to sensitize the normal lung cells. Thus, targeting FLIP not only preferentially sensitizes NSCLC cells to death receptor-targeted agents, but also to chemotherapeutic agents commonly used to treat this disease. Importantly, we were able to show that silencing FLIP in vivo retarded NSCLC xenograft growth. Moreover, we showed for the first time that targeting FLIP in vivo can significantly enhance the antitumour effects of chemotherapy. Collectively, these results strongly suggest that FLIP is a key regulator of chemoresistance in NSCLC. Of note, FLIP silencing was able to induce apoptosis in both type I (H460) and type II (A549) NSCLC cells. Moreover, we found that FLIP silencing sensitized both type I and type II NSCLC cells to TRAIL-and chemotherapyinduced apoptosis. Thus, targeting FLIP either alone or in combination with chemotherapy or TRAIL may be a viable therapeutic strategy, regardless of whether the apoptotic signal requires amplification through the intrinsic pathway.
It has been reported that even when both DR4 and DR5 are expressed, only one may function to induce apoptosis. 20 Using receptor-specific siRNAs, we found that induction of apoptosis after FLIP silencing was mediated by DR4 and *** *** After tumor establishment (day 6), the xenografts were injected with 1000 pmol siRNA thrice a week for 2 weeks. Mice were treated with cisplatin (CDDP; 5 mg/kg; IP) once a week for 2 weeks as indicated DR5, but not Fas. Consistent with this, the cell lines, which expressed the highest total levels of DR4 and DR5 were the most sensitive to FLIP siRNA-induced apoptosis. Although the two normal lung cell lines expressed low levels of DR4, it should be noted that FLIP siRNA-induced apoptosis was only partially blocked in NSCLC cells in which DR4 was downregulated, indicating that FLIP silencing can induce apoptosis in cells with low DR4 expression as long as DR5 is expressed. Therefore, lack of DR4 expression cannot explain the complete resistance of the normal lung cell lines to FLIP silencing. Of note, we found that blocking binding of TRAIL to its receptors failed to inhibit FLIP siRNA-induced apoptosis in NSCLC cells, indicating that downregulating FLIP triggers ligand-independent activation of DR4-and DR5-mediated apoptosis. The synergistic interactions between FLIP siRNA and both TRAIL and cisplatin were also found to be mediated through both DR4 and DR5. Several studies have indicated that after ligation, death receptors cluster into lipid rafts, which are rich in cholesterol and sphingolipids. 25 Recently, Dumitru and Gulbins 14 showed that TRAIL treatment resulted in generation of ceramide at the cell membrane, which clustered with DR5 in a range of cancer cell lines. We found that FLIP silencing (in the absence of TRAIL co-treatment) induced clustering of DR5 in ceramideenriched membrane platforms in NSCLC cells, but not normal lung cells. Furthermore, inhibiting co-localization of DR5 and ceramide or blocking ceramide production abrogated FLIP siRNA-induced apoptosis in NSCLC cells, suggesting that this co-localization is required to induce cell death. Caspase 8 activity has been found to be critical for ASM-regulated, ceramide-mediated FasL-induced Fas clustering and cell death. 25 We found that only a relatively modest Bthreefold downregulation of procaspase 8 was necessary to block FLIP siRNA-induced apoptosis. Moreover, a Bthreefold upregulation of procaspase 8 in BEAS-2B cells was sufficient to sensitize these otherwise resistant cells to FLIP siRNA and TRAIL. Thus, relatively small changes in the levels of procaspase 8 expression seem to profoundly affect sensitivity to FLIP siRNA and TRAIL, which may explain why the normal lung cell line models, which have lower procaspase 8 expression, are less sensitive to FLIP silencing or TRAIL. This finding may have important clinical relevance given the high percentage of NSCLC tumors that we observed to overexpress procaspase 8.
Con
Numerous determinants of TRAIL sensitivity have been identified, including expression levels of FLIP, XIAP, Bcl-2 family members, TRAIL decoy receptors as well as TRAIL receptor glycosylation. [26] [27] [28] [29] [30] [31] [32] [33] In addition, reduced or absent caspase 8 expression has been shown to result in lack of sensitivity to TRAIL-induced apoptosis in a restricted number of cancers, including neuroblastoma and small-cell lung cancer. 12, 34 However, caspase 8 expression is retained in most cancers and a polymorphism in the caspase 8 promoter that decreases caspase 8 expression has been associated with reduced susceptibility to multiple cancers, including lung cancer. 35 In this study, we found that procaspase 8 was actually overexpressed in a panel of 20 NSCLCs. The apparent selection for procaspase 8 overexpression in NSCLC is intriguing and suggests that in the presence of FLIP, procaspase 8 may activate proliferative or pro-survival signaling pathways, for example through activation of NFkB. 36 Although the NSCLC cells overexpressed procaspase 8, we found that constitutive caspase 8 activity was similar in NSCLC and normal lung cells. However, when FLIP was silenced, caspase 8 was activated and apoptosis was induced in the NSCLC cells, but not in the normal lung cells. Collectively, our results suggest that FLIP actively prevents overexpressed procaspase 8 being activated by DR4 and DR5 in NSCLC cells, both constitutively and in the context of chemotherapy/TRAIL treatment. Thus, targeting FLIP may preferentially sensitize NSCLC cells to chemotherapy and TRAIL and may therefore represent a promising therapeutic strategy for NSCLC. Furthermore, tumor procaspase 8 expression may be a useful biomarker for the effectiveness of such strategies.
Materials and Methods
Reagents. Recombinant human TRAIL was purchased from Calbiochem (Gibbstown, NJ, USA), reconstituted in filter-sterilized PBS/0.1% bovine serum albumin (BSA) as a 20 ng/ml stock solution and stored at À701C. Anti-TRAIL neutralizing antibody was obtained from R&D Systems (Minneapolis, MN, USA). Nystatin was obtained from Sigma, Dorset, UK. Interferon gamma (IFN-g) was purchased from Calbiochem.
Cell culture. All the cell lines were maintained in 5% CO 2 at 371C. H460, H157 and H727 cells were maintained in DMEM supplemented with 10% bovine calf serum, 1 mmol/l sodium pyruvate, 2 mmol/l L-glutamine and 50 mg/ml penicillin/ streptomycin (all from Invitrogen, Paisley, UK). A549 cells were maintained in DMEM supplemented with 10% bovine calf serum, 2 mmol/l L-glutamine and 50 mg/ ml penicillin/streptomycin. 34LU cells were maintained in DMEM supplemented with 10% bovine calf serum, 2 mmol/l L-glutamine, 100 mmol/l non-essential amino acids and 50 mg/ml penicillin/streptomycin. BEAS-2B cells were maintained in F12 Ham Medium (Invitrogen) supplemented with 10% bovine calf serum, 2 mmol/l L-glutamine, 100 mmol/l non-essential amino acids (Invitrogen) and 50 mg/ml penicillin/streptomycin.
Western blotting. Western Blots were carried out as previously described. 18 FLIP (NF6; Alexis, San Diego, CA, USA), Caspase 8 (12F5; Alexis) and Poly-ADPRibose-Polymerase-1 (PARP; eBioscience, San Diego, CA, USA) mouse monoclonal antibodies were used in conjunction with a horseradish peroxidaseconjugated sheep anti-mouse secondary antibody (Amersham, Buckinghamshire, UK). Caspase 9, caspase 3 and phospho-STAT1 (Tyr701) (Cell Signalling, Beverly, MA, USA) and DR4 (Calbiochem) rabbit polyclonal antibodies were used in conjunction with a horseradish peroxidase-conjugated sheep anti-rabbit secondary antibody (Amersham). DR5 (N-19) goat polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used in conjunction with a horseradish peroxidase-conjugated donkey anti-goat secondary antibody (Santa Cruz). Equal loading was assessed using a b-tubulin mouse monoclonal primary antibody (Sigma) or b-actin mouse monoclonal primary antibody (Sigma). For xenograft samples, FLIP was detected using the FLIP (Dave-2; Alexis) rat monoclonal antibody in conjunction with a horseradish peroxidase-conjugated goat anti-rat secondary antibody (Amersham).
Patient samples. The NSCLC patients were all part of an EU Biomarkers Study, and patient consent was received before the surgery. Patients' details are given in Table 1 . The patients' tumors were resected at St. James' Hospital, Dublin. Immediately after resection, a consultant pathologist identified the normal and tumor tissues and cut a piece of each. The tissues were then immediately snap frozen in liquid nitrogen. Proteins were extracted using standard protein extraction procedures and western blot analysis carried out as described above.
Flow cytometry. Apoptosis was determined using propidium iodide (PI) staining to evaluate the percentage of cells with DNA content o2N as previously described. 18 For annexin V/PI analysis, cells were harvested and analyzed according to manufacturer's instructions (BD Biosciences, Oxford, UK). Cell surface expression of death receptors was performed as previously described. 18 
